S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
OTCMKTS:HNSBF

Hansa Biopharma AB (publ) (HNSBF) Stock Price, News & Analysis

$2.93
0.00 (0.00%)
(As of 03/28/2024 ET)
Today's Range
$2.93
$2.93
50-Day Range
$2.65
$3.30
52-Week Range
$2.26
$5.30
Volume
N/A
Average Volume
425 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
HNSBF stock logo

About Hansa Biopharma AB (publ) Stock (OTCMKTS:HNSBF)

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments with rare immunological conditions using its proprietary enzyme technology platform. The company's lead drug candidate is Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the potential of combining imlifidase and efgartigimod to potentially be used in the acute and chronic setting of autoimmune diseases and transplantation. It also has a collaboration with Genethon to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

HNSBF Stock Price History

HNSBF Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Hansa Medical AB earnings: here's what to expect
Hansa Biopharma AB HNSA
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Hansa Biopharma half year report 2023
Hansa Biopharma provides Q1 update
Hansa Biopharma interim report January-March 2023
Hansa Biopharma AB (publ) (0RC7.IL)
See More Headlines
Receive HNSBF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hansa Biopharma AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:HNSBF
CIK
N/A
Fax
N/A
Employees
168
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Søren Tulstrup M.Sc (Age 59)
    President & CEO
    Comp: $15.26M
  • Mr. C. Evan Ballantyne (Age 64)
    Chief Financial Officer
  • Dr. Christian Kjellman (Age 57)
    Senior VP & COO
  • Dr. Hitto Kaufmann Ph.D. (Age 53)
    Chief Scientific Officer
  • Ms. Eva-Maria Joed (Age 55)
    Vice President of Finance & Administration
  • Mr. Klaus Sindahl
    VP & Head of Investor Relations
  • Ms. Anne Säfström Lanner (Age 55)
    Senior VP & Chief Human Resources Officer
  • Mr. Emanuel Björne (Age 51)
    VP & Head of Business Development
  • Dr. Lena Winstedt (Age 55)
    Head of Science
  • Ms. Vincenza Nigro M.B.A.
    VP & Head of Medical Affairs

HNSBF Stock Analysis - Frequently Asked Questions

How have HNSBF shares performed in 2024?

Hansa Biopharma AB (publ)'s stock was trading at $2.2570 at the beginning of 2024. Since then, HNSBF stock has increased by 29.8% and is now trading at $2.93.
View the best growth stocks for 2024 here
.

Are investors shorting Hansa Biopharma AB (publ)?

Hansa Biopharma AB (publ) saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 572,600 shares, an increase of 7.7% from the January 31st total of 531,800 shares. Based on an average daily trading volume, of 200 shares, the short-interest ratio is presently 2,863.0 days.
View Hansa Biopharma AB (publ)'s Short Interest
.

How do I buy shares of Hansa Biopharma AB (publ)?

Shares of HNSBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:HNSBF) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners